Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > probably a good news for Egrifta

<< Previous

Bullboard Posts

Next >>

Comment by PWIB123on Jan 05, 2023 10:38am

142 Views

Post# 35204705

RE:probably a good news for Egrifta

Agreed. I have no idea how large an impact on sales this could make, but even if it's not deemed news worthy, you'd think at this point, they would announce it to continue to reinforce the increasing sales projections.

LouisW wrote: https://www.globenewswire.com/news-release/2023/01/05/2583627/0/en/World-Orphan-Drug-Alliance-Announces-Agreement-with-Theratechnologies-for-the-Distribution-of-EGRIFTA-SV.html

Not sure why th not to announe this....

<< Previous

Bullboard Posts

Next >>

3 Mid-Sized Stocks to Consider This Season